Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon

In this segment, the expert panel discusses how Acoltremon fits within the broader treatment landscape for dry eye disease, particularly in relation to anti-inflammatory therapies. The faculty compare Acoltremon’s mechanism—a neuromodulatory stimulation of basal tear production—to traditional approaches such as topical steroids and immunomodulators. One expert explains that while steroids remain valuable for short-term control of inflammation, many patients have cycled through these agents without meaningful improvement. For these individuals, Acoltremon offers a distinctly different option that provides a perceptible increase in natural tear volume, often giving patients immediate feedback that therapy is working.

The panel emphasizes the importance of understanding the entire dry eye disease cascade—from tear film instability to hyperosmolarity, ion channel dysfunction, epithelial damage, and inflammation—to determine where Acoltremon can provide benefit. They note that because it modulates TRPM8 and related ion channels, it can be used alone or in combination with other therapies to restore ocular surface homeostasis. Experts conclude that Acoltremon fits broadly across patient types, particularly those dependent on artificial tears or those who have plateaued on cyclosporine or steroids, and they anticipate its role will continue to expand as clinical experience grows.